NTRA

SEC source: 0001415889-25-018838 · form4-07012025_090710.xml · nonDerivative · entry 2

Marcus Gail Boxer · CIK 0001702176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,118

F3 · shares: Represents the issuance of RSUs to the Reporting Person. 25% of the RSUs vest immediately and the remaining RSUs vest in three equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-018838 · form4-07012025_090710.xml · nonDerivative · entry 1

Marcus Gail Boxer · CIK 0001702176 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,847

F1 · shares: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 12, 2026. The RSUs will become fully vested in the event that the Issuer is subject to a change in control.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-018834 · form4-07012025_090701.xml · nonDerivative · entry 1

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,158

F1 · shares: Represents the issuance of restricted stock units (RSUs) that shall vest in full on June 12, 2026. The RSUs will become fully vested in the event that the Issuer is subject to a change in control.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-023477 · form4-09022025_090901.xml · nonDerivative · entry 2

Chapman Rowan E · CIK 0001786240 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,616

F3 · shares: Represents the issuance of RSUs to the Reporting Person. 25% of the RSUs vest immediately and the remaining RSUs vest in three equal quarterly installments thereafter.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-023477 · form4-09022025_090901.xml · nonDerivative · entry 1

Chapman Rowan E · CIK 0001786240 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,345

F1 · shares: Represents the issuance of restricted stock units ("RSUs") that shall vest in full on June 12, 2026. The RSUs will become fully vested in the event that the Issuer is subject to a change in control.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001415889-25-020158 · form4-07222025_090708.xml · nonDerivative · entry 3

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,766

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024, as amended on March 14, 2025.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.12 to $171.74 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-020158 · form4-07222025_090708.xml · nonDerivative · entry 2

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,044

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024, as amended on March 14, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.11 to $171.10 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 248,774

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.7250 to $167.6950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-020158 · form4-07222025_090708.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,674

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024, as amended on March 14, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.00 to $170.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 9

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 37,282

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.16 to $165.55 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 8

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 37,981

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.10 to $165.01 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 7

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 38,406

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.08 to $163.12 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 6

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 38,606

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.04 to $162.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 5

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 37,282

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.48 to $165.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 4

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 37,829

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.45 to $165.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 3

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 38,379

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.12 to $163.66 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-017917 · form4-06202025_090601.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 38,582

F3 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.04 to $162.58 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-017920 · form4-06202025_090601.xml · nonDerivative · entry 7

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 30,000

SEC source: 0001415889-25-016790 · form4-06112025_090601.xml · nonDerivative · entry 2

Marcus Gail Boxer · CIK 0001702176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,704

F1 · shares: .The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

SEC source: 0001415889-25-016790 · form4-06112025_090601.xml · nonDerivative · entry 1

Marcus Gail Boxer · CIK 0001702176 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,304

F1 · shares: .The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.00 to $164.99 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-015716 · form4-06042025_090603.xml · nonDerivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 133,205

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

SEC source: 0001415889-25-015716 · form4-06042025_090603.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 133,305

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.88 to $158.5450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-015716 · form4-06042025_090603.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 133,770

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.74 to $157.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-015716 · form4-06042025_090603.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,915

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.73 to $156.69 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-015715 · form4-06042025_090601.xml · nonDerivative · entry 3

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 179,071

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.88 to $158.6250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-015715 · form4-06042025_090601.xml · nonDerivative · entry 2

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,547

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.63 to $157.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-015715 · form4-06042025_090601.xml · nonDerivative · entry 1

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,670

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.63 to $156.5350 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-017920 · form4-06202025_090601.xml · nonDerivative · entry 6

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 35,000

SEC source: 0001415889-25-020155 · form4-07222025_090701.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,799

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on June 10, 2022

SEC source: 0001415889-25-020156 · form4-07222025_090703.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,556

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on June 10, 2022.

SEC source: 0001415889-25-017920 · form4-06202025_090601.xml · nonDerivative · entry 5

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 45,000

SEC source: 0001415889-25-017920 · form4-06202025_090601.xml · nonDerivative · entry 4

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 55,000

SEC source: 0001415889-25-017920 · form4-06202025_090601.xml · nonDerivative · entry 3

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 64,000

SEC source: 0001415889-25-017920 · form4-06202025_090601.xml · nonDerivative · entry 2

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 74,000

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 14

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 38,782

F7 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F14 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.67 to $159.40 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 13

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 39,490

F7 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F13 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.64 to $158.53 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 12

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 2 Trust

Disclosed balance after: 39,873

F7 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.64 to $157.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 11

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 38,782

F7 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F9 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 10

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 38,882

F7 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.62 to $159.59 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 9

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 39,572

F7 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.57 to $158.06 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 8

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Indirect · By Caraluna 1 Trust

Disclosed balance after: 39,879

F7 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.

F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.53 to $157.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 7

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 251,844

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 6

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 251,944

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.71 to $163.67 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 5

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 252,344

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.68 to $162.65 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 4

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 253,575

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.55 to $160.06 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 3

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 254,175

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.00 to $158.02 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 254,282

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.31 to $155.75 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-012842 · form4-05132025_090501.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 254,522

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

SEC source: 0001415889-25-011882 · form4-05022025_090504.xml · nonDerivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,205

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

SEC source: 0001415889-25-011882 · form4-05022025_090504.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136,536

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.97 to $151.5450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.